A MULTICENTER, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS (PK) AND PHARMACODYNAMIC (PD) EFFECTS OF POSIPHEN&#174; IN SUBJECTS WITH MILD ALZHEIMER’S DISEASE/ MCI.

Posiphen (buntanetap) - Annovis Bio

https://www.ctad-alzheimer.com/files/files/JPAD%20CTAD%20abstracts.pdf

D. Galasko1; M. Farlow2; B. Lucey3; L. Honig4; A. Moghekar5; D. Elbert6; R. Bateman3; J. Momper1; R. Thomas1; R. Rissman1; A. Balasubramaniam1; M. Maccecchini7; H. Feldman1

Dec 9, 2022